<DOC>
	<DOC>NCT01037244</DOC>
	<brief_summary>Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of subjects with erectile dysfunction (ED).</brief_summary>
	<brief_title>Treatment of Erectile Dysfunction I</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Male, at least 19 years of age Stable monogamous relationship for at least 6 months with a consenting female partner who is at least 19 years of age, vaginal intercourse is a required study activity History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration Partner is not pregnant or lactating History of newonset symptomatic coronary artery disease within the last 3 months or a history of myocardial infarction or cardiac surgical procedure within six months Cardiac arrhythmias requiring antiarrhythmic treatment Symptomatic congestive heart failure Taking nitrate medication in any form Uncontrolled diabetes (HbA1c ≥ 13%) Hypersensitivity to phosphodiesterase type 5 (PDE5) inhibitors such as Viagra®, Cialis® or Levitra® Previously failed to respond to PDE5 inhibitors such as Viagra®, Cialis® or Levitra®</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>